Press release +

Prothea Technologies, the private medical technology company with a vision to offer lung cancer biopsy and treatment in a single hospital visit, is pleased to announce that its technology will feature at the 8^th Annual Conference of the American Association for Bronchology and Interventional Pulmonology (August 14-16, Austin, Texas).

In a session on Diagnostic Bronchoscopy, at 07.15am on Thursday August 14^th, Dr Adam Marshall, Consultant Interventional Pulmonologist at Royal Infirmary of Edinburgh, will present a poster entitled “Molecular Visualisation and Direct Ablation of Distal Lung with a Miniaturised Flexible Microendoscope Platform Deploying Real Time Artificial Intelligence”.

Dr Marshall is the Principal Investigator for the Precision Lung clinical trial that, subject to the relevant clearances, is expected to start later in 2025. The trial will record the safety, procedural success and diagnostic yield of the Prothea Imaging and Biopsy technology in a series of patients with suspicious lung nodules. It is co-sponsored by the University of Edinburgh and NHS Lothian.

The Prothea Imaging and Biopsy system and the Ablation system are in development and are not currently cleared for use in the United States or any other country.

Notes for Editors

Lung cancer is the third most common form of cancer in the U.S. and annually claims more lives than breast, prostate and colon cancer combined. Screening programmes facilitate the early detection of suspicious lesions, but delivering value from these initiatives requires a significant increase in biopsy performance, presenting a challenge for hospitals already grappling with low biopsy yields and false negatives.

Prothea has developed a Microendoscope that combines with an Image Processing System to characterise small lesions, in situ, at a molecular level, for greater biopsy accuracy. A laser ablation probe is in development for the treatment of lesions immediately following biopsy. The integration of these two systems (real-time imaging and ablation) is designed to streamline biopsy and treatment into a single hospital visit, reducing time-to-treat from weeks to minutes, thereby relieving hospital pressures and improving patient outcomes.

Prothea’s Image Processing Systems measure the differential in time, between healthy and abnormal tissue, for the round trip of light from and to a laser source. Proprietary software will be developed, enhanced by artificial intelligence, to evaluate large volume data sets – developing in-procedure information to support clinical decisions.

Prothea Technologies is a spinout from the Universities of Edinburgh and Bath and in April 2024 completed a €12m Series A financing provided by Earlybird Venture Capital, Mérieux Equity Partners and NRW.BANK.

For further information, please contact:
Dr. Anne Moore, COO
Email: [email protected]

Prothea Technologies Limited City Point, 3rd Floor, 65 Haymarket Terrace, Edinburgh, Scotland, EH12 5HD

Registered company number SC701542